| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18795086 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 102 journal articles in the PubMed database | Email to a friend | | |
| Skoumalova I, Vondrakova J, Rohon P, et al.
Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy. [Journal Article]
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008 Jun; 152(1):121-3.
Abstract | Full Citation | Find Related Articles | | Braziel RM, Launder TM, Druker BJ, et al.
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. [Journal Article]
Blood 2002 Jul 15; 100(2):435-41.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kantarjian H, O'Brien S, Cortes J, et al.
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. [Evaluation Studies, Journal Article]
Cancer 2003 Oct 1; 98(7):1430-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cohen MH, Johnson JR, Pazdur R
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. [Clinical Trial, Journal Article]
Clin Cancer Res 2005 Jan 1; 11(1):12-9.
Abstract | Full Citation | Find Related Articles | | Ali R, Ozkalemkaş F, Ozkocaman V, et al.
Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. [Case Reports, Journal Article]
Jpn J Clin Oncol 2004 Apr; 34(4):215-7.
Abstract | Full Citation | Find Related Articles | | Piazza RG, Magistroni V, Franceschino A, et al.
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. [JOURNAL ARTICLE]
Blood Cells Mol Dis 2006 Aug 11.
Abstract | Full Citation | | Kantarjian H, Talpaz M, O'Brien S, et al.
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. [Journal Article]
Cancer 2003 May 1; 97(9):2225-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | DeAngelo DJ, Hochberg EP, Alyea EP, et al.
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. [Journal Article]
Clin Cancer Res 2004 Aug 1; 10(15):5065-71.
Abstract | Full Citation | Find Related Articles | | Kantarjian HM, Talpaz M, O'Brien S, et al.
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
Clin Cancer Res 2002 Jul; 8(7):2177-87.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
